Key facts
- This page summarizes Eric Trachtenberg's Form 4 filing for Kala Pharmaceuticals, Inc. (KALA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2023, 20:00.
Eric Trachtenberg - 22 Jun 2023 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)
- Reporting relationship
- General Counsel, Chief Compliance Officer and Secretary
- Issuer ticker
- KALA
- Reported as of
- 22 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2023, 20:00:25 UTC
- Prior SEC filing
- 02 Jun 2023
- Next SEC filing
- 05 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Trachtenberg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Trachtenberg filed Form 4 for Kala Pharmaceuticals, Inc. (KALA) on 23 Jun 2023.
Change
- Previous filing in this sequence was filed on 02 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +37,559
- Change %
- +138%
- Price
- $0.000000
- Shares after
- 64,693
- Date
- 22 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +50,078
- Change %
- Price
- $0.000000
- Shares after
- 50,078
- Date
- 22 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,078
- Exercise price
- $14.56
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
Footnote F2
Includes 62,874 unvested RSUs.
Footnote F3
This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
SEC remarks
General Counsel, Chief Compliance Officer and Secretary